Correction of cross-linker sensitivity of Fanconi anemia group F cells by CD33-mediated protein transferHOLMES, Rebecca K; HARUTYUNYAN, Karine; SHAH, Maulik et al.Blood. 2001, Vol 98, Num 13, pp 3817-3822, issn 0006-4971Article

Targeting FMS-Related Tyrosine Kinase Receptor 3 With the Human Immunoglobulin G1 Monoclonal Antibody IMC-EB10YOUSSOUFIAN, Hagop; ROWINSKY, Eric K; TONRA, James et al.Cancer. 2010, Vol 116, Num 4, pp 1013-1017, issn 0008-543X, 5 p., SUPConference Paper

Review : Monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapyYOUSSOUFIAN, Hagop; HICKLIN, Daniel J; ROWINSKY, Eric K et al.Clinical cancer research. 2007, Vol 13, Num 18, issn 1078-0432, 5544s-5548s, 2Conference Paper

A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG₁ Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid MalignanciesKUENEN, Bart; WITTEVEEN, Petronella O; VOEST, Emile E et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1915-1923, issn 1078-0432, 9 p.Article

Rationale for the Development of IMC-3G3, a Fully Human Immunoglobulin G Subclass 1 Monoclonal Antibody Targeting the Platelet-Derived Growth Factor Receptor αSHAH, Gaurav D; LOIZOS, Nick; YOUSSOUFIAN, Hagop et al.Cancer. 2010, Vol 116, Num 4, pp 1018-1026, issn 0008-543X, 9 p., SUPConference Paper

Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 studyLORUSSO, Patricia M; KRISHNAMURTHI, Smitha; YOUSSOUFIAN, Hagop et al.Investigational new drugs. 2014, Vol 32, Num 2, pp 303-311, issn 0167-6997, 9 p.Article

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal CancerREIDY, Diane Lauren; VAKIANI, Efsevia; DONTABHAKTUNI, Aruna et al.Journal of clinical oncology. 2010, Vol 28, Num 27, pp 4240-4246, issn 0732-183X, 7 p.Article

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)SCHWARTZ, Jonathan D; ROWINSKY, Eric K; YOUSSOUFIAN, Hagop et al.Cancer. 2010, Vol 116, Num 4, pp 1027-1032, issn 0008-543X, 6 p., SUPConference Paper

IMC-A12, a human IgG₁ monoclonal antibody to the insulin-like growth factor I receptorROWINSKY, Eric K; YOUSSOUFIAN, Hagop; TONRA, James R et al.Clinical cancer research. 2007, Vol 13, Num 18, issn 1078-0432, 5549s-5555s, 2Conference Paper

Cancer predisposition caused by elevated mitotic recombination in Bloom miceGUANGBIN LUO; SANTORO, Irma M; MCDANIEL, Lisa D et al.Nature genetics. 2000, Vol 26, Num 4, pp 424-429, issn 1061-4036Article

A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRα) monoclonal antibody, in patients with advanced solid tumorsCHIOREAN, E. Gabriela; SWEENEY, Christopher; YOUSSOUFIAN, Hagop et al.Cancer chemotherapy and pharmacology. 2014, Vol 73, Num 3, pp 595-604, issn 0344-5704, 10 p.Article

Anti-Transforming Growth Factor β Receptor II Antibody Has Therapeutic Efficacy against Primary Tumor Growth and Metastasis through Multieffects on Cancer, Stroma, and Immune CellsZHAOJING ZHONG; DRISCOLL CARROLL, Kyla; BURTRUM, Douglas et al.Clinical cancer research (Print). 2010, Vol 16, Num 4, pp 1191-1205, issn 1078-0432, 15 p.Article

Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G₁ Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2SPRATLIN, Jennifer L; COHEN, Roger B; MEROPOL, Neal J et al.Journal of clinical oncology. 2010, Vol 28, Num 5, pp 780-787, issn 0732-183X, 8 p.Article

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neckBONNER, James A; HARARI, Paul M; OVE, Roger et al.The New England journal of medicine. 2006, Vol 354, Num 6, pp 567-578, issn 0028-4793, 12 p.Article